Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy

Letrozole withdrawal response in locally advanced breast cancer

(2011) M. Lambertini et al.   ANNALS OF ONCOLOGY

Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer

(2011) Amit Agrawal et al.   World Journal of Surgical Oncology

New Strategies in Estrogen Receptor-Positive Breast Cancer

(2010) S. R. D. Johnston   CLINICAL CANCER RESEARCH

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer

(2009) Matthew J. Ellis et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

(2008) Robert J. Paridaens et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY